An In-Depth Analysis of Dersimelagon (MT-7117): A Novel Oral MC1R Agonist for Photodermatoses and Fibrotic Disease

Executive Summary

Dersimelagon (MT-7117) is an investigational, orally administered, selective small-molecule agonist of the melanocortin 1 receptor (MC1R), developed in-house by Mitsubishi Tanabe Pharma Corporation. The compound represents a significant potential advancement in the treatment of rare photodermatoses, primarily erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), conditions characterized by severe, painful phototoxicity. Its mechanism of action involves stimulating the production of photoprotective eumelanin in the skin, thereby increasing tolerance to sunlight. Positive results from a Phase 2 study (ENDEAVOR) demonstrated a clinically and statistically significant increase in pain-free sun exposure for patients with EPP/XLP. This success has led to a pivotal global Phase 3 trial (INSPIRE), for which enrollment is complete, positioning Dersimelagon as a potential first-in-class oral therapy for these debilitating conditions. Its primary competitive advantage lies in its convenient oral route of administration compared to the currently approved implantable therapy.

The drug has also been investigated for diffuse cutaneous systemic sclerosis (dcSSc), leveraging the anti-inflammatory and anti-fibrotic properties associated with MC1R activation. However, a Phase 2 trial in this indication failed to meet its primary composite endpoint related to skin and organ involvement, though it revealed a promising secondary signal in preserving lung function. This report provides a comprehensive analysis of Dersimelagon's chemical properties, pharmacological profile, complete clinical development history, regulatory status, and a detailed competitive landscape analysis for its key indications, ultimately assessing its therapeutic potential and strategic position within the pharmaceutical market.

1.0 Introduction to Dersimelagon: A Novel, Oral, Selective MC1R Agonist

1.1 Drug Profile and Chemical Characteristics

Dersimelagon, identified by the development code MT-7117 and its radiolabeled variant [14C] MT-7117, is classified as an investigational small molecule drug.[1] Its status as a non-peptide compound is a critical design feature, distinguishing it from endogenous melanocortin hormones and first-generation peptide-based analogues, and enabling its formulation for oral administration.[2] The molecular structure of Dersimelagon is complex, incorporating several chemical classes, including carboxylic acids, cyclopentanes, fluorinated hydrocarbons, phenyl ethers, piperidines, and pyrrolidines.[1]

Key chemical and registry identifiers for the compound are:

• CAS Number: 1835256-48-8 [6]
• DrugBank ID: DB18007
• Molecular Weight: 675.8 g/mol [6]
• InChI Key: MUNWOYRHJPWQNE-GMFUQMJFSA-N [6]

The synthesis of Dersimelagon is a multi-step process. It involves the construction of a core pyrrolidine ring, which can be achieved through methods such as the cyclization of a γ-aminoketone or via [3+2] cycloaddition reactions. Subsequent steps include palladium-catalyzed cross-coupling reactions to introduce aryl groups and specific fluorination steps to complete the molecule.[6] For preclinical in vivo studies, the compound is often formulated as a suspension in vehicles such as 0.5% methylcellulose, sometimes with 0.1% Tween 80, to improve its oral bioavailability.[6]

Regarding its physical properties, Dersimelagon exhibits a solubility of 25 mg/mL in dimethyl sulfoxide (DMSO) at 37°C. Its stability is temperature-dependent; it is stable for at least one month when stored in DMSO at -20°C but shows approximately 15% degradation over 72 hours in aqueous buffers at room temperature (25°C). The lyophilized powder form demonstrates high stability, remaining viable for two years or more when stored at -80°C under a nitrogen atmosphere.[6]

1.2 Originator and Development History

Dersimelagon is an in-house discovery developed by Mitsubishi Tanabe Pharma Corporation (MTPC), one of Japan's oldest and most established pharmaceutical companies, with a history dating back to 1678.[1] The clinical development and commercialization efforts in North America are managed by its wholly-owned subsidiary, Mitsubishi Tanabe Pharma America, Inc. (MTPA), which is headquartered in Jersey City, New Jersey.[2] For the European Union, development activities appear to be coordinated through Mitsubishi Tanabe Pharma GmbH, located in Duesseldorf, Germany.[9] Dersimelagon is a key asset within MTPC's immuno-inflammation therapeutic franchise, which is one of the company's strategic focus areas alongside central nervous system disorders, diabetes, and oncology.[7]

1.3 Overview of Therapeutic Indications and Development Status

Dersimelagon is being developed primarily for rare diseases where photosensitivity and fibrosis are key pathological features.

• Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP): This is the lead and most advanced indication for Dersimelagon. The program has successfully completed a Phase 2 proof-of-concept study (ENDEAVOR) and is currently in a global, pivotal Phase 3 trial named INSPIRE (NCT06144840). As of May 2025, enrollment for this study was officially completed.[1] An associated open-label extension study (NCT05005975) is also underway to gather long-term safety and tolerability data.[13]
• Diffuse Cutaneous Systemic Sclerosis (dcSSc): This is a secondary indication that has been explored. A Phase 2 clinical trial (NCT04440592) in this patient population has been completed, with results showing a failure to meet the primary endpoint but revealing a potential signal in a key secondary measure.[1]
• Autoimmune Disorders: This therapeutic area is listed as a potential field of interest for Dersimelagon, though no specific development programs have been publicly reported.[1]

Characteristic	Detail
Name	Dersimelagon
Alternative Names	MT-7117, [14C] MT-7117
DrugBank ID	DB18007
CAS Number	1835256-48-8
Type	Small Molecule, Non-peptide
Originator	Mitsubishi Tanabe Pharma Corporation (In-house)
Mechanism of Action	Selective Melanocortin 1 Receptor (MC1R) Agonist
Route of Administration	Oral
Highest Development Phase (Indication)	Phase 3 (Erythropoietic Protoporphyria / X-Linked Protoporphyria)Phase 2 (Diffuse Cutaneous Systemic Sclerosis)
Table 1: Dersimelagon Drug Profile Summary 1

2.0 Scientific Foundation: Mechanism of Action and Pharmacological Profile

2.1 The Melanocortin 1 Receptor (MC1R) as a Therapeutic Target

The therapeutic rationale for Dersimelagon is centered on the melanocortin 1 receptor (MC1R), a Class A G protein-coupled receptor (GPCR) that is a member of the five-receptor melanocortin family (MC1R-MC5R).[6] MC1R is most widely recognized for its pivotal role in regulating skin and hair pigmentation. When activated by its primary endogenous ligand, α-melanocyte-stimulating hormone (α-MSH), it initiates signaling pathways that lead to the production of melanin.[17]

The therapeutic potential of targeting MC1R extends far beyond pigmentation. The receptor is expressed on a diverse array of cell types that are central to inflammatory and fibrotic processes, including various immune cells (monocytes, macrophages, neutrophils), endothelial cells, keratinocytes, and fibroblasts.[6] This broad expression pattern underpins the pleiotropic effects of MC1R activation, which include potent anti-inflammatory and anti-fibrotic activities. This dual functionality makes MC1R an exceptionally attractive therapeutic target for complex diseases like EPP and SSc, which involve both photosensitivity and underlying inflammatory or fibrotic components.[17]

2.2 Molecular Interactions: Dersimelagon's Selective Agonism and Downstream Signaling Cascades

Dersimelagon is engineered as a highly selective agonist for MC1R.[1] Preclinical assessments have confirmed its superior affinity for the human MC1R over other melanocortin receptors, with a half-maximal effective concentration (

EC50​) of 8.16 nM for human MC1R.[4] This selectivity is a key pharmacological feature, designed to minimize off-target effects that could arise from activating other MCRs. For instance, avoiding significant activation of MC4R, which is a key regulator of appetite and energy homeostasis, is clinically desirable.[6]

The mechanism of action begins when Dersimelagon binds to MC1R. This binding induces a conformational change in the receptor, which in turn activates its associated G protein, the stimulatory G protein (Gs).[18] The activated Gs protein stimulates the enzyme adenylyl cyclase, which catalyzes the conversion of adenosine triphosphate (ATP) into the second messenger cyclic adenosine monophosphate (cAMP).[6]

The subsequent rise in intracellular cAMP levels is the critical step that initiates downstream signaling. Elevated cAMP activates Protein Kinase A (PKA), which then phosphorylates a cascade of downstream effector proteins. This includes the activation of the CREB (cAMP response element-binding protein) and MITF (Microphthalmia-associated transcription factor) transcriptional networks.[19] This canonical MC1R/cAMP/PKA signaling pathway is the central axis through which Dersimelagon exerts its diverse pharmacodynamic effects.[24]

2.3 Pharmacodynamic Effects: Induction of Melanogenesis, Anti-inflammatory, and Anti-fibrotic Pathways

The activation of the MC1R signaling cascade by Dersimelagon translates into three primary pharmacodynamic effects with therapeutic relevance.

• Melanogenesis and Photoprotection: The most direct and well-understood effect is the induction of melanogenesis. The activation of the MITF transcription factor by the cAMP/PKA pathway upregulates the expression of key melanogenic enzymes, including tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT).[6] This enzymatic activity preferentially synthesizes eumelanin, the dark brown-black pigment that is significantly more effective at photoprotection than the red-yellow pheomelanin. Eumelanin acts as a natural sunscreen, absorbing and scattering ultraviolet (UV) radiation and visible light, thereby protecting skin cells from phototoxic damage.[18] This is the principal mechanism of action intended for the treatment of EPP and XLP. This effect was visually confirmed in preclinical models, where oral administration of Dersimelagon led to notable coat color darkening in mice, and was quantified in human Phase 1 studies, where multiple doses produced a measurable increase in skin melanin density.[6]
• Anti-inflammatory Effects: MC1R activation exerts broad anti-inflammatory effects through multiple pathways. It is known to suppress the activation of Nuclear Factor-kappa B (NF-κB), a master transcription factor that drives the expression of numerous inflammatory genes. This leads to the inhibition of pro-inflammatory cytokine production, including tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and IL-6.[17] Furthermore, MC1R signaling has been reported to induce the production of IL-10, a potent anti-inflammatory cytokine.[17] This provides a strong rationale for its investigation in inflammatory conditions.
• Anti-fibrotic Effects: Dersimelagon has demonstrated direct anti-fibrotic activity. In vitro experiments have shown that it can inhibit the activation of human dermal fibroblasts, a key event in the pathogenesis of fibrosis. Specifically, it suppresses the transforming growth factor-beta (TGF-β)-induced upregulation of ACTA2 mRNA, the gene that encodes for α-smooth muscle actin (α-SMA), a hallmark protein of the pro-fibrotic myofibroblast phenotype.[20] This direct effect on fibroblasts forms the central hypothesis for its use in treating fibrotic diseases like systemic sclerosis.

2.4 Clinical Pharmacology: A Comprehensive Review of ADME, Pharmacokinetics, and Drug-Drug Interaction Potential

The clinical pharmacology profile of Dersimelagon has been characterized through preclinical studies and a comprehensive Phase 1 trial in healthy volunteers.

• Absorption, Distribution, Metabolism, and Excretion (ADME):
• Absorption: Following oral administration, Dersimelagon is rapidly absorbed. In healthy human volunteers, the median time to reach maximum plasma concentration (Tmax) was approximately 2 hours, with a range of 4 to 5 hours observed across different days of multiple dosing.[4]
• Distribution: The drug is highly bound to plasma proteins, with a binding rate of 98.3% in humans, suggesting limited free drug in circulation.[6]
• Metabolism: Dersimelagon undergoes extensive metabolism, primarily occurring in the liver. The two main metabolic pathways are Phase II glucuronidation, where an acyl glucuronide metabolite (M06a) is formed at the drug's carboxylic acid group by UGT enzymes (UGT1A1/UGT2B7), and Phase I oxidation, involving hydroxylation and demethylation reactions mediated by cytochrome P450 enzymes (predominantly CYP3A4 and CYP2C8 in humans).[6]
• Excretion: The primary route of elimination is through the feces, with over 90% of the administered radioactive dose recovered in feces within five days. Urinary excretion is negligible, accounting for less than 1% of the dose.[28] This excretion profile suggests a mechanism of hepatic metabolism (glucuronidation), followed by elimination of the metabolite into the bile, and subsequent enzymatic hydrolysis of the glucuronide conjugate back to the parent compound within the gastrointestinal tract, a process known as enterohepatic recirculation.[6]
• Pharmacokinetics (PK):
• Systemic exposure, as measured by the area under the curve (AUC) and maximum concentration (Cmax), increases in a slightly more than dose-proportional manner across a single-dose range of 1 mg to 600 mg.[4]
• The mean elimination half-life (t1/2​) after multiple dosing was observed to be between 10.6 and 19.0 hours, a profile that supports a convenient once-daily dosing regimen.[4]
• Steady-state plasma concentrations were generally achieved by the fifth day of continuous dosing.[4]
• Importantly, Phase 1 studies found no clinically significant effects of age or race on the pharmacokinetic profile of Dersimelagon, suggesting that dose adjustments based on these demographic factors may not be necessary.[4]
• Drug-Drug Interaction (DDI) Potential:
• The risk of clinically significant drug-drug interactions is predicted to be low. This is because Dersimelagon is metabolized by multiple, redundant pathways involving both CYP and UGT enzymes, making it less susceptible to inhibition or induction of a single pathway.[6]
• This hypothesis was supported by a physiologically based pharmacokinetic (PBPK) modeling study, which predicted that co-administering Dersimelagon with substrates of common drug transporters, such as atorvastatin and rosuvastatin, would not result in clinically meaningful changes in their plasma exposure.[29]

3.0 Preclinical Evidence and Rationale for Clinical Development

3.1 In Vitro and In Vivo Proof-of-Concept

The foundation for the clinical development of Dersimelagon was built on a robust body of preclinical evidence that established its mechanism of action and in vivo activity. In vitro assays confirmed that Dersimelagon acts as a selective and full agonist for the melanocortin 1 receptor (MC1R).[17] Further cell-based studies using a mouse B16F1 melanoma cell line demonstrated that the drug induced melanin production in a clear, concentration-dependent manner, providing direct evidence of its intended pharmacodynamic effect.[4]

This in vitro proof-of-concept was successfully translated to in vivo models. Oral administration of Dersimelagon to healthy mice produced a visually striking and significant darkening of their coat color, a direct and unambiguous confirmation of systemic eumelanin induction.[6] Similarly, studies in non-human primates (monkeys) showed that oral dosing led to reversible skin pigmentation.[4] Collectively, these foundational studies were critical. They not only validated the drug's mechanism of action and target engagement but also confirmed that it was orally bioavailable and capable of producing the desired biological effect (melanogenesis) systemically. This provided a compelling scientific rationale to advance Dersimelagon into clinical trials for human photodermatoses, such as EPP, where enhancing natural photoprotection is the primary therapeutic goal.

3.2 Disease-Modifying Effects in Preclinical Models of Systemic Sclerosis

The rationale for investigating Dersimelagon in systemic sclerosis (SSc) stemmed from its potential anti-inflammatory and anti-fibrotic properties, which were rigorously evaluated in well-established bleomycin (BLM)-induced murine models of the disease.[17]

In a prophylactic setting, where Dersimelagon was administered at the start of or prior to BLM-induced injury, the drug demonstrated significant protective effects. At doses of 0.3 mg/kg/day and higher, it markedly inhibited the development of both skin fibrosis, as measured by tissue collagen content, and lung inflammation, as quantified by serum levels of the lung injury biomarker SP-D, lung weight, and the expression of inflammatory genes in the lung tissue.[20] Treatment also led to an improvement in the body weight loss typically associated with this severe disease model.[30]

In a more clinically relevant therapeutic setting, where treatment was initiated after fibrosis was already established, Dersimelagon (at doses of 3 mg/kg/day and higher) still showed significant efficacy. It suppressed the further progression of skin thickening and reduced the number of activated myofibroblasts, the key cell type responsible for excessive collagen deposition.[20]

Mechanistic studies within these models provided further insight. Gene array analysis of treated tissues revealed that Dersimelagon modulated pathways associated with the activation of key inflammatory cells (macrophages, monocytes, neutrophils) and suppressed signaling related to vascular dysfunction, including angiogenesis and vasculogenesis.[20] Furthermore, serum protein profiling identified that Dersimelagon suppressed multiple SSc-related biomarkers, such as P-selectin, osteoprotegerin, and growth and differentiation factor-15 (GDF-15).[20]

To bridge these findings to human disease, immunohistochemical analyses were performed on skin biopsies from SSc patients. These analyses confirmed that MC1R, the target of Dersimelagon, is expressed on the key cell types implicated in SSc pathology, including monocytes/macrophages, neutrophils, endothelial cells, and fibroblasts.[20] This crucial translational link confirmed that the drug's target is present and accessible in the human disease state, providing a strong justification for its clinical investigation in SSc.

The strength and breadth of these preclinical results in SSc models—showing significant effects on skin fibrosis, lung inflammation, and relevant biomarkers—painted a very promising picture. However, the subsequent human trial results were more modest, particularly concerning skin fibrosis. This discrepancy highlights a well-known challenge in drug development: the translational gap between animal models and human disease. The bleomycin-induced mouse model, while a standard and valuable tool, induces an acute inflammatory and fibrotic response that may not fully recapitulate the chronic, complex, and heterogeneous nature of human SSc. Factors such as disease duration, genetic background, and the intricate interplay of the human immune system can lead to different therapeutic responses. While the preclinical data provided a strong rationale to proceed, the clinical outcome underscores that even robust animal model efficacy does not guarantee success in human trials, especially in a multifaceted disease like SSc.

Model/System	Key Finding	Implication for Clinical Development
In Vitro (Human/Mouse Cells)	Confirmed selective MC1R agonism and induction of melanogenesis.	Validated the drug's primary mechanism of action and target engagement.
In Vivo (Healthy Mice/Monkeys)	Oral administration induced systemic melanogenesis (coat darkening, skin pigmentation).	Provided in vivo proof-of-concept for oral bioavailability and pharmacodynamic effect. Justified development for photodermatoses.
In Vivo (Bleomycin-induced SSc Mouse Model)	Showed both prophylactic and therapeutic efficacy against skin fibrosis and lung inflammation. Suppressed key inflammatory and fibrotic biomarkers.	Provided a strong rationale for investigating Dersimelagon in Systemic Sclerosis.
Table 2: Summary of Key Preclinical Findings 4

4.0 Clinical Development Program in Erythropoietic and X-Linked Protoporphyria (EPP/XLP)

The clinical development of Dersimelagon for EPP and XLP has followed a logical, stepwise progression from establishing safety in healthy individuals to demonstrating proof-of-concept efficacy in patients, and is now in the final phase of pivotal testing for regulatory approval.

4.1 Phase 1 Studies in Healthy Volunteers (NCT02834442): Establishing Safety and Dose

The first-in-human evaluation of Dersimelagon was a randomized, double-blind, placebo-controlled Phase 1 study designed to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses.[4] The study was notable for its inclusion of diverse cohorts to proactively assess potential differences across populations, enrolling healthy adult volunteers from different racial backgrounds (White and Black) and age groups (18-55 years and ≥65 years).[4]

The results demonstrated that Dersimelagon was generally well-tolerated. The most frequently reported treatment-emergent adverse events (TEAEs) following multiple doses were lentigines (freckles) in 52.8% of participants and skin hyperpigmentation in 50.0%.[4] These events, while common, were expected pharmacodynamic effects directly related to the drug's mechanism of stimulating melanin production and were not considered serious safety concerns.

The pharmacokinetic analysis confirmed a profile suitable for clinical development, showing rapid absorption and a half-life that supports a convenient once-daily dosing schedule. The PK profile was found to be consistent across the different age and race subgroups studied.[4] Pharmacodynamically, the study provided crucial evidence of target engagement in humans. While single doses did not produce a measurable change, multiple-dose regimens of 150 mg and 300 mg resulted in observable increases in skin melanin density (MD), confirming that the drug was biologically active at achievable exposures in humans.[4]

4.2 Phase 2 ENDEAVOR Trial (NCT03520036): A Deep Dive into Efficacy and Safety Results

Building on the positive Phase 1 data, the ENDEAVOR study was a multi-center, randomized, double-blind, placebo-controlled Phase 2 trial designed to establish proof-of-concept for Dersimelagon in the target patient population.[5] The trial enrolled 102 adult patients, aged 18 to 75, with a confirmed diagnosis of EPP (n=93) or the related condition XLP (n=9). Participants were randomized in a 1:1:1 ratio to receive one of three treatments: placebo, Dersimelagon 100 mg, or Dersimelagon 300 mg, administered orally once daily for a period of 16 weeks.[31]

The trial successfully met its primary efficacy endpoint. Both dose levels of Dersimelagon demonstrated a statistically significant and clinically meaningful increase in the time patients could spend in sunlight before experiencing the first prodromal symptoms (such as burning, tingling, or itching) compared to the placebo group at the 16-week mark.[5]

• The 100 mg dose group showed a least-squares mean difference from placebo of +53.8 minutes of symptom-free sun exposure per day (p=0.008).[5]
• The 300 mg dose group showed an even greater benefit, with a least-squares mean difference from placebo of +62.5 minutes per day (p=0.003).[5]

In addition to the primary endpoint, secondary endpoint analyses suggested an improvement in patient-reported quality of life (QoL) in the Dersimelagon arms compared to placebo, further supporting the clinical benefit of the treatment.[25] The safety profile observed in the trial was consistent with earlier findings and the drug's known mechanism. Dersimelagon was generally well-tolerated, with the most common adverse events being nausea, freckles, headache, and skin hyperpigmentation.[26]

Parameter	Description
Study ID	NCT03520036 (ENDEAVOR)
Phase	2
Design	Randomized, double-blind, placebo-controlled, multi-center
Population	102 adults (18-75 years) with confirmed EPP or XLP
Arms (1:1:1)	1. Placebo once daily (QD)2. Dersimelagon 100 mg QD3. Dersimelagon 300 mg QD
Duration	16 weeks
Primary Endpoint	Change from baseline in average daily time to first prodromal symptom during sunlight exposure at Week 16
Table 3: Phase 2 ENDEAVOR Trial Design 5

Endpoint/Result	Details
Primary Endpoint (vs. Placebo)	100 mg Dose: +53.8 minutes/day (LS Mean Difference), p=0.008300 mg Dose: +62.5 minutes/day (LS Mean Difference), p=0.003
Key Secondary Endpoints	Suggested improvement in Quality of Life (QoL) measures.
Key Adverse Events	Nausea, freckles, headache, skin hyperpigmentation.
Table 4: Phase 2 ENDEAVOR Trial - Summary of Key Results 5

4.3 The Pivotal Phase 3 INSPIRE Trial (NCT06144840): Design, Endpoints, and Current Status

Following the success of the Phase 2 study, MTPC initiated the pivotal INSPIRE trial, a global, randomized, double-blind, placebo-controlled Phase 3 study designed to provide the definitive evidence of efficacy and safety required for regulatory submission.[2] The study has expanded its patient population to include approximately 150 adult and adolescent patients with EPP or XLP, with an age range of 12 to 75 years. The inclusion of adolescents (ages 12-17) is a key expansion from the Phase 2 trial and addresses a significant unmet need, as there are currently no approved treatments for this younger population.[2]

Based on the Phase 2 results, the study will evaluate a single dose of Dersimelagon at 200 mg, administered once daily, against a placebo over a 16-week double-blind treatment period.[12] After this period, participants will have the option to roll over into a 36-week open-label extension, during which all subjects can receive the active 200 mg dose.[12]

The trial's endpoints are designed to confirm the Phase 2 findings:

• Primary Endpoint: The primary endpoint is the change from baseline in the average daily sunlight exposure time (in minutes) to the first prodromal symptom at Week 16, a direct replication of the successful Phase 2 primary endpoint.[12]
• Secondary Endpoints: Key secondary endpoints include the Patient Global Impression of Change (PGIC), the total number of sunlight-induced pain events, and the total number of phototoxic reactions during the treatment period.[12]

As of May 2025, patient enrollment for the INSPIRE study was officially completed. This marks a critical milestone for the program, and topline data from the 16-week primary analysis are anticipated in the fall of 2025.[1]

Parameter	Description
Study ID	NCT06144840 (INSPIRE)
Phase	3
Design	Global, randomized, double-blind, placebo-controlled
Population	Approximately 150 adults & adolescents (12-75 years) with EPP or XLP
Arms (1:1)	1. Dersimelagon 200 mg once daily (QD)2. Placebo QD
Duration	16-week double-blind period, followed by an optional 36-week open-label extension
Primary Endpoint	Change from baseline in average daily sunlight exposure time to first prodromal symptom at Week 16
Key Secondary Endpoints	Patient Global Impression of Change (PGIC), total number of pain events, total number of phototoxic reactions
Table 5: Pivotal Phase 3 INSPIRE Trial Design 2

4.4 Evaluating Long-Term Safety and Tolerability in Extension Studies (NCT05005975)

To complement the pivotal trial data, a multicenter, open-label, long-term extension study (NCT05005975) is actively enrolling patients who have completed prior Dersimelagon trials.[13] The primary objective of this study is to gather comprehensive data on the long-term safety and tolerability of chronic oral Dersimelagon administration.[14] This study is essential for constructing the robust, long-term safety database required by regulatory agencies for marketing approval and for providing critical insights into the durability of the treatment effect and any potential cumulative toxicities that may emerge over time.

5.0 Clinical Investigation in Systemic Sclerosis (SSc)

5.1 Rationale and Design of the Phase 2 Trial (NCT04440592)

Leveraging the potent anti-inflammatory and anti-fibrotic effects observed in preclinical SSc models, Mitsubishi Tanabe Pharma initiated a Phase 2 clinical trial (NCT04440592) to evaluate Dersimelagon in patients with diffuse cutaneous systemic sclerosis (dcSSc).[17] The study was a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial designed to assess efficacy and safety over a 52-week period.[16]

The trial enrolled 76 adult participants (≥18 years) with early-stage (≤5 years since first non-Raynaud's manifestation) and active dcSSc. Key inclusion criteria included a modified Rodnan Skin Score (mRSS) between 15 and 45, indicating significant skin thickening, and evidence of active disease.[16] Participants were required to be on a stable background dose of standard-of-care immunosuppressive therapy, such as mycophenolate mofetil or methotrexate.[16]

The primary endpoint for the study was the American College of Rheumatology Composite Response Index in Diffuse Systemic Sclerosis (ACR CRISS) score at Week 52. The ACR CRISS is a sophisticated composite endpoint that calculates a probability of improvement (from 0 to 1) by integrating changes across five core domains: the mRSS (skin), percent predicted forced vital capacity (%pFVC, lung), the Health Assessment Questionnaire-Disability Index (HAQ-DI), and both patient and physician global assessments of health.[16]

Parameter	Description
Study ID	NCT04440592
Phase	2
Design	Randomized, double-blind, placebo-controlled, multi-center
Population	76 adults with early, active diffuse cutaneous SSc (dcSSc) on stable background therapy
Arms (1:1)	1. Dersimelagon once daily (QD)2. Placebo QD
Duration	52 weeks
Primary Endpoint	American College of Rheumatology Composite Response Index in SSc (ACR CRISS) score at Week 52
Key Secondary Endpoints	Change in mRSS, %pFVC, HAQ-DI from baseline
Table 6: Phase 2 Systemic Sclerosis Trial Design 16

5.2 Analysis of Efficacy and Safety Results: Interpreting the Primary and Secondary Endpoint Data

The results of the Phase 2 trial in dcSSc were mixed and nuanced. The study did not meet its primary efficacy endpoint, as there was no statistically significant difference in the ACR CRISS composite score between the Dersimelagon and placebo groups after 52 weeks of treatment. Furthermore, there were no statistically significant changes observed in key components of the CRISS score, including the mRSS (a direct measure of skin thickness) and the HAQ-DI (a measure of physical disability).[34]

However, a potentially important signal emerged from the analysis of a key secondary endpoint: pulmonary function. The data showed a greater numerical improvement from baseline in percent predicted forced vital capacity (%pFVC) in the group treated with Dersimelagon compared to the placebo group.[34] This finding suggests that while the drug may not have had a measurable effect on the skin, it might possess a beneficial effect on preserving lung function.

This observation was further supported by a subset analysis. Among participants who completed the full 52 weeks of treatment at the higher 300 mg dose, the improvement in %pFVC from baseline was nominally statistically significant when compared to placebo. This effect was notably absent in the subgroup of patients whose dose had been reduced to 200 mg due to adverse events.[34]

From a safety perspective, Dersimelagon was generally well-tolerated. However, consistent with its mechanism of action, skin hyperpigmentation was the most frequently reported TEAE that prompted either dose reduction or treatment discontinuation.[34] This presents a clinical challenge, as the data suggest the higher, less-tolerated dose may be necessary to achieve the potential pulmonary benefit.

Endpoint/Result	Details
Primary Endpoint (ACR CRISS)	Not statistically significant. The trial failed to meet its primary endpoint.
Key Secondary Endpoints	mRSS (Skin Score): No statistical change.%pFVC (Lung Function): Showed greater numerical improvement vs. placebo. This improvement was nominally statistically significant in the subgroup of patients who completed treatment on the 300 mg dose.
Key Adverse Events	Skin hyperpigmentation was the most common TEAE leading to dose reduction or discontinuation.
Table 7: Phase 2 Systemic Sclerosis Trial - Summary of Key Results 34

5.3 Future Outlook and Potential Pathways for Dersimelagon in SSc

The failure to meet the primary endpoint in the broad dcSSc population represents a significant setback for this indication. The lack of a demonstrable effect on skin fibrosis, a core feature of the disease, makes a broad approval for dcSSc highly unlikely based on the current data.

However, the positive signal observed in pulmonary function offers a potential, albeit more challenging, path forward. The numerical improvement in %pFVC, particularly the nominally significant result in the higher-dose completer group, suggests that Dersimelagon may have a therapeutic role specifically in the treatment of SSc-associated Interstitial Lung Disease (SSc-ILD), which is a leading cause of mortality in SSc patients.

Pursuing this path would require a new, dedicated clinical trial designed with %pFVC as the primary endpoint and specifically enrolling an SSc-ILD population. This represents a high-risk, high-reward strategy. The tolerability issues that led to dose reductions would need to be carefully managed, as the data imply that maintaining the higher dose is crucial for the potential lung benefit. The development landscape for SSc-ILD is also competitive, meaning Dersimelagon would need to demonstrate a compelling benefit-risk profile against existing and emerging therapies.

6.0 Regulatory and Commercialization Pathway

6.1 Navigating the Regulatory Landscape: FDA and EMA Special Designations

Recognizing the high unmet medical need in EPP and XLP, both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted Dersimelagon special regulatory designations to facilitate its development and review.

• U.S. Food and Drug Administration (FDA):
• Fast Track Designation: Granted in June 2018 for the EPP/XLP indication. This designation is intended to expedite the review of drugs that treat serious conditions and fill an unmet medical need, allowing for more frequent interactions with the FDA throughout the development process.[3]
• Orphan Drug Designation: Granted on June 8, 2020, for the "treatment of cutaneous variants of porphyria." This designation provides significant incentives, including tax credits for clinical trials, waiver of prescription drug user fees, and the potential for seven years of market exclusivity in the U.S. upon approval for the designated rare disease.[1]
• European Medicines Agency (EMA):
• Orphan Designation: Granted in March 2022 for the "treatment of erythropoietic protoporphyria." Similar to the FDA designation, this provides incentives within the European Union, most notably ten years of market exclusivity post-approval.[9]

In addition, a Paediatric Investigation Plan (PIP) has been agreed upon with the EMA for the development of Dersimelagon in systemic sclerosis. This is a mandatory development plan for all new medicines in the EU to ensure that the needs of pediatric populations are considered.[38]

Agency	Designation	Indication	Date Granted
FDA (U.S.)	Fast Track	Erythropoietic Protoporphyria / X-Linked Protoporphyria	June 2018
FDA (U.S.)	Orphan Drug	Treatment of cutaneous variants of porphyria	June 2020
EMA (EU)	Orphan Designation	Treatment of erythropoietic protoporphyria	March 2022
Table 8: Regulatory Designations for Dersimelagon 5

6.2 Projected Path to Market and Key Milestones

The immediate commercialization pathway for Dersimelagon is entirely dependent on the outcome of the pivotal Phase 3 INSPIRE trial in EPP/XLP.

• Key Upcoming Milestone: The most critical near-term event is the release of topline data from the INSPIRE study, which is anticipated in the fall of 2025.[12]
• Next Steps: Assuming the trial successfully replicates the positive efficacy and safety findings from the Phase 2 ENDEAVOR study, MTPC would be positioned to proceed with regulatory submissions. This would likely involve filing a New Drug Application (NDA) with the FDA and a Marketing Authorisation Application (MAA) with the EMA, potentially in late 2025 or early 2026.

The development path for the systemic sclerosis indication is currently undefined. Given the Phase 2 results, a new clinical program specifically targeting SSc-ILD would be necessary, placing any potential regulatory filing for this indication several years further into the future.

7.0 Competitive and Strategic Analysis

7.1 The Therapeutic Landscape for Erythropoietic Protoporphyria

The market for EPP treatments is characterized by a high unmet need, a single approved therapy, and an emerging pipeline with a distinct mechanism of action.

7.1.1 Current Standard of Care: A Comparative Analysis with Afamelanotide (SCENESSE®)

The current standard of care for adults with EPP is afamelanotide (marketed as SCENESSE® by Clinuvel Pharmaceuticals), which has been the sole approved therapy in the U.S. and Europe for several years.[39] Like Dersimelagon, afamelanotide is an MC1R agonist, an analogue of the endogenous α-MSH, and works by stimulating eumelanin production to provide photoprotection.[18] Clinical and real-world data have shown that afamelanotide provides a dramatic clinical benefit, significantly increasing patients' tolerance to light and markedly improving their quality of life.[40]

The key difference between the two drugs lies in their administration. Afamelanotide is delivered as a solid, bioresorbable subcutaneous implant that must be administered by a trained healthcare professional every two months.[39] This sets a high efficacy bar for any new entrant but also presents a potential vulnerability related to convenience and patient preference.

7.1.2 The Emerging Pipeline: Positioning Against Bitopertin and Other Investigational Agents

The most significant threat in the EPP pipeline is bitopertin, being developed by Disc Medicine.[42] Bitopertin represents a fundamentally different therapeutic approach. It is an oral inhibitor of glycine transporter 1 (GlyT1), an enzyme involved in the heme biosynthesis pathway. By inhibiting GlyT1, bitopertin aims to reduce the production of the toxic metabolite protoporphyrin IX (PPIX), which is the root cause of the photosensitivity and potential liver toxicity in EPP.[42]

Bitopertin is advancing rapidly. Following successful end-of-Phase 2 discussions with the FDA, Disc Medicine plans to initiate its pivotal Phase 3 APOLLO trial by mid-2025. Critically, the company is also pursuing an accelerated approval pathway based on the reduction of PPIX levels as a surrogate endpoint, with a potential New Drug Application (NDA) filing targeted for the second half of 2025.[42]

7.1.3 Dersimelagon's Differentiating Attributes and Potential Market Positioning

Dersimelagon's market position will be defined by its performance relative to these two key competitors.

• Versus Afamelanotide: Dersimelagon's primary and most compelling differentiator is its oral route of administration. The convenience of a once-daily tablet is a significant advantage over a professionally administered subcutaneous implant required every two months.[48] If the INSPIRE trial demonstrates efficacy that is comparable or non-inferior to the established benefits of afamelanotide, this convenience factor could allow Dersimelagon to capture a substantial share of the market, particularly among patients who are needle-averse or prefer the autonomy of an oral therapy.
• Versus Bitopertin: The competition here is based on mechanism. Dersimelagon offers a photoprotective strategy, creating a "shield" of eumelanin, while bitopertin offers a disease-modifying strategy by reducing the underlying toxic metabolite. These are not mutually exclusive and could potentially be used in a complementary fashion. However, bitopertin's mechanism has the potential added benefit of addressing the risk of EPP-associated liver disease by lowering systemic PPIX levels, an aspect that Dersimelagon's mechanism does not directly target.[19] The race to market will be tight, with both companies targeting regulatory filings in a similar timeframe.

Drug Name	Company	Mechanism of Action	Route of Administration	Development Status	Key Differentiator
Dersimelagon	Mitsubishi Tanabe Pharma	Selective MC1R Agonist	Oral (once daily)	Phase 3 (Topline data H2 2025)	Oral convenience, non-peptide
Afamelanotide (SCENESSE®)	Clinuvel Pharmaceuticals	MC1R Agonist	Subcutaneous Implant (every 2 months)	Approved (US/EU)	Established efficacy, proven QoL benefit
Bitopertin	Disc Medicine	Glycine Transporter 1 (GlyT1) Inhibitor	Oral	Phase 3 (Planned mid-2025), potential accelerated NDA filing H2 2025	Disease-modifying (reduces PPIX), potential liver benefit
Table 9: Competitive Landscape Analysis for EPP/XLP 2

7.2 The Therapeutic Landscape for Systemic Sclerosis

7.2.1 Overview of a Complex and Crowded Market

In stark contrast to the niche EPP market, the therapeutic landscape for systemic sclerosis is complex, heterogeneous, and features a crowded and active development pipeline.[49] There is a profound unmet need for a true disease-modifying agent, but the field is competitive. Current treatments are primarily aimed at managing specific organ manifestations and include a range of immunosuppressants (mycophenolate, methotrexate, rituximab, tocilizumab) and the antifibrotic agent nintedanib, which is approved for SSc-ILD.[53] The development pipeline is robust, with over 50 different therapies being investigated by numerous companies, targeting a wide array of pathological pathways including inflammation, fibrosis, and vascular dysfunction.[50]

7.2.2 Assessing the Viability of Dersimelagon's Potential Role

Given this competitive environment, Dersimelagon's path forward in SSc is fraught with challenges. The failure of the Phase 2 trial to meet its broad primary endpoint for dcSSc makes it highly unlikely to succeed in this general indication.[34]

The only remaining viable path is a highly focused strategy targeting SSc-ILD, leveraging the positive signal seen in the %pFVC secondary endpoint. However, even in this niche, it would face competition from established therapies like nintedanib and other emerging agents. Furthermore, the tolerability profile, specifically the skin hyperpigmentation that led to dose reductions, could be a significant commercial liability. Patients with SSc already suffer from skin manifestations, and an additional, visible side effect may be poorly accepted unless the efficacy in preserving lung function is exceptionally strong and clearly demonstrated in a dedicated pivotal trial.

8.0 Synthesis, Strategic Insights, and Recommendations

8.1 Critical Assessment of the Dersimelagon Clinical Program

The clinical development program for Dersimelagon presents a tale of two distinct indications with divergent outcomes and future prospects. The program for EPP and XLP is a model of focused, successful drug development. It is built on a clear biological rationale, supported by positive Phase 1 and Phase 2 data, and is now progressing through a well-designed pivotal Phase 3 trial with a clear regulatory pathway supported by orphan and fast-track designations. Success in this indication appears plausible and is contingent on the final INSPIRE trial results.

Conversely, the program in systemic sclerosis has encountered significant hurdles. While based on strong preclinical rationale, the Phase 2 trial failed to demonstrate efficacy on its primary composite endpoint, which included the key domain of skin fibrosis. The emergence of a positive signal in lung function offers a potential lifeline, but it reframes the drug from a broad anti-fibrotic agent to a more niche, potential therapy for SSc-ILD. This represents a much higher-risk proposition, requiring a new and costly clinical program in a competitive field, further complicated by tolerability issues at the potentially required therapeutic dose. The dual mechanisms of photoprotection and anti-fibrosis, while stemming from the same receptor, have proven to be unequal in their clinical translatability, forcing a strategic bifurcation of the asset's future.

8.2 Strengths, Weaknesses, Opportunities, and Threats (SWOT) Analysis

• Strengths:
• Novel Oral Administration: Its primary strength is the convenient once-daily oral formulation, a significant advantage over the approved injectable implant for EPP.
• Strong Phase 2 EPP Data: The ENDEAVOR trial demonstrated statistically significant and clinically meaningful efficacy, providing a strong foundation for the Phase 3 program.
• Favorable Regulatory Status: Fast Track and Orphan Drug designations from both the FDA and EMA de-risk and potentially accelerate the regulatory and commercial pathway for EPP.
• Weaknesses:
• Unproven Long-Term Safety: As an investigational agent, the long-term safety profile is still being established in extension studies.
• Mechanism-Linked Adverse Events: Skin hyperpigmentation and freckles are common and directly linked to the drug's mechanism. While potentially acceptable in EPP, this was a liability in the SSc trial and could be a commercial challenge.
• Failed Primary Endpoint in SSc: The lack of efficacy in the broad dcSSc indication limits the drug's potential scope and raises questions about its anti-fibrotic potency in humans.
• Opportunities:
• First-in-Class Oral Agent for EPP: If approved, it would be the first oral therapy for EPP, potentially capturing a significant market share based on patient and physician preference for convenience.
• Life-Cycle Management: The melanogenic mechanism provides a clear scientific rationale for expansion into other photodermatoses, most notably vitiligo, offering a path for future growth.
• Threats:
• Strong Incumbent Competition: Afamelanotide is an established therapy with proven, dramatic efficacy in EPP, setting a high bar for a new entrant.
• Emerging Mechanistic Competition: The disease-modifying oral agent bitopertin is advancing rapidly and targets the underlying cause of EPP, which may be perceived as a superior long-term strategy.
• Pivotal Trial Risk: The INSPIRE trial could fail to meet its endpoints or reveal an unfavorable benefit-risk profile, which would halt the EPP program.

8.3 Future Directions: Potential in Other Photodermatoses and Unexplored Avenues

Beyond its current development programs, the mechanism of action of Dersimelagon suggests potential applicability in other dermatological conditions.

• Vitiligo: The most logical potential follow-on indication is vitiligo, a condition characterized by a loss of melanocytes and skin depigmentation.[26] The ability of Dersimelagon to stimulate melanogenesis could theoretically aid in repigmentation, potentially as an adjunct to other therapies like phototherapy. However, this would require dedicated clinical trials. The competitive landscape for vitiligo is also evolving rapidly, with JAK inhibitors and other targeted therapies showing promise, meaning Dersimelagon would need to demonstrate a compelling efficacy and safety profile to compete.[56]
• Atopic Dermatitis: The anti-inflammatory properties of MC1R agonism provide a theoretical rationale for its use in atopic dermatitis.[17] However, this is an extremely competitive therapeutic area dominated by highly effective biologics like dupilumab and a robust pipeline of other agents.[57] The systemic side effect profile of Dersimelagon, particularly skin pigmentation changes, would likely make it less competitive against more targeted and better-tolerated options in this indication.

These potential future indications should be viewed as long-term life-cycle management opportunities, contingent upon the initial success and market adoption of Dersimelagon in its lead indication of EPP.

8.4 Concluding Remarks and Strategic Recommendations

Dersimelagon stands at a critical juncture. Its future is almost entirely dependent on the forthcoming results of the Phase 3 INSPIRE trial. The program in EPP/XLP has been executed effectively, targeting a clear unmet need with a drug that offers a significant convenience advantage over the current standard of care. A positive outcome from INSPIRE would position Dersimelagon as a major new therapy for this rare disease community and validate the oral small-molecule approach for MC1R agonism. The success or failure of this program will likely influence the development strategies for other companies targeting photodermatoses.

Strategic recommendations for the developer, Mitsubishi Tanabe Pharma, are therefore clear:

1. Prioritize EPP/XLP: The primary focus must be on the successful completion and analysis of the INSPIRE trial. A positive result should be followed by prompt and well-prepared regulatory submissions to the FDA and EMA to capitalize on its lead as a potential first-in-class oral agent.
2. Re-evaluate the SSc Program: Following the Phase 2 results, the broad dcSSc indication should be deprioritized. A rigorous, data-driven assessment is required to determine if the potential benefit in SSc-ILD warrants the significant investment and risk of a new, dedicated Phase 3 trial in a highly competitive space.
3. Plan for Life-Cycle Management: Contingent on success in EPP, a strategic evaluation of vitiligo as a follow-on indication should be initiated. This would leverage the extensive safety and mechanistic data generated from the EPP program to potentially expand the drug's market value in the long term.

In conclusion, Dersimelagon holds considerable promise as a transformative oral therapy for patients with EPP and XLP. Its journey highlights both the potential of targeted small-molecule development and the inherent challenges of translating preclinical findings into clinical success across different complex diseases. The upcoming data from the INSPIRE trial will be the definitive determinant of its future.

Works cited

1. Mitsubishi Tanabe Pharma - Dersimelagon - AdisInsight - Springer, accessed July 3, 2025, https://adisinsight.springer.com/drugs/800046518
2. First Patient Enrolled in MTPA INSPIRE Study of Investigational Dersimelagon for EPP and XLP - Mitsubishi Tanabe Pharma America, accessed July 3, 2025, https://www.mt-pharma-america.com/media/press-releases/2024/first-patient-enrolled-in-mtpa-inspire-study-of-investigational-dersimelagon-for-epp-and-xlp
3. First Patient Enrolled in MTPA INSPIRE Study of Investigational Dersimelagon for EPP and XLP - Press Releases - Mitsubishi Tanabe Pharma America, accessed July 3, 2025, https://www.mt-pharma-america.com/media/news/press-releases/2024/03/19/first-patient-enrolled-in-mtpa-inspire-study-of-investigational-dersimelagon-for-epp-and-xlp
4. Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist, accessed July 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10229459/
5. Start of a Phase 3 Clinical Trial of MT-7117 for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP) and X-Linked Protop, accessed July 3, 2025, https://www.mt-pharma.co.jp/e/news/assets/pdf/e_MTPC200615.pdf
6. Dersimelagon | 1835256-48-8 - Benchchem, accessed July 3, 2025, https://www.benchchem.com/product/b607062
7. Pipeline | R&D | Mitsubishi Tanabe Pharma Corporation, accessed July 3, 2025, https://www.mt-pharma.co.jp/e/develop/pipeline.html
8. MC1R - Drugs, Indications, Patents - Synapse, accessed July 3, 2025, https://synapse.patsnap.com/target/c7675b5235644c7db45ae370d50070ea
9. Union Register of medicinal products - Public health - European Commission, accessed July 3, 2025, https://ec.europa.eu/health/documents/community-register/html/o2585.htm
10. State of New Product Development (As of January 25, 2025), accessed July 3, 2025, https://www.mt-pharma.co.jp/e/develop/assets/pdf/e_pipeline2412.pdf
11. Mitsubishi Tanabe Pharma America Announces Presentations at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD) - PR Newswire, accessed July 3, 2025, https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-announces-presentations-at-the-30th-world-congress-on-parkinsons-disease-and-related-disorders-iaprd-302447655.html
12. Mitsubishi Tanabe Pharma America Announces Completion of Enrollment for its Phase 3 INSPIRE Study of Investigational Dersimelagon in Patients with EPP and XLP, accessed July 3, 2025, https://www.mt-pharma-america.com/media/press-releases/2025/mitsubishi-tanabe-pharma-america-announces-completion-of-enrollment-for-its-phase-3-inspire-study-of-investigational-dersimelagon-in-patients-with-epp-and-xlp
13. Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | ClinicalTrials.gov, accessed July 3, 2025, https://www.clinicaltrials.gov/study/NCT05005975?cond=Autosomal%20erythropoietic%20protoporphyria%20OR%20%22EPP%22&aggFilters=status:not%20rec&viewType=Table&rank=2
14. Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) - UCSF Clinical Trials, accessed July 3, 2025, https://clinicaltrials.ucsf.edu/trial/NCT05005975
15. Our Clinical Trials - Mitsubishi TanabePharma America, accessed July 3, 2025, https://www.mt-pharma-america.com/science/our-clinical-trials
16. Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis | ClinicalTrials.gov, accessed July 3, 2025, https://clinicaltrials.gov/study/NCT04440592?intr=Dersimelagon%20&rank=7
17. (PDF) Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis - ResearchGate, accessed July 3, 2025, https://www.researchgate.net/publication/363192942_Dersimelagon_a_novel_oral_melanocortin_1_receptor_agonist_demonstrates_disease-modifying_effects_in_preclinical_models_of_systemic_sclerosis
18. Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic ..., accessed July 3, 2025, https://www.mdpi.com/1422-0067/24/15/12152
19. Illuminating Dersimelagon: A Novel Agent in the Treatment of Erythropoietic Protoporphyria and X-Linked Protoporphyria, accessed July 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10819203/
20. Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis - OUCI, accessed July 3, 2025, https://ouci.dntb.gov.ua/en/works/73ooBdo7/
21. Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis - PubMed, accessed July 3, 2025, https://pubmed.ncbi.nlm.nih.gov/36050717/
22. POS0467 DERSIMELAGON, A NOVEL ORAL MELANOCORTIN 1 RECEPTOR AGONIST, DEMONSTRATES DISEASE-MODIFYING EFFECTS IN PRECLINICAL MODELS OF SYSTEMIC SCLEROSIS - ResearchGate, accessed July 3, 2025, https://www.researchgate.net/publication/361617284_POS0467_DERSIMELAGON_A_NOVEL_ORAL_MELANOCORTIN_1_RECEPTOR_AGONIST_DEMONSTRATES_DISEASE-MODIFYING_EFFECTS_IN_PRECLINICAL_MODELS_OF_SYSTEMIC_SCLEROSIS
23. Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects - PMC, accessed July 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10418475/
24. Melanocortin Agonists & Antagonists - BOC Sciences, accessed July 3, 2025, https://www.bocsci.com/tag/melanocortin-mc-receptors-238.html?page=2
25. Conquering sunlight sensitivity: Dersimelagon's promise in photodermatoses, accessed July 3, 2025, https://researchoutreach.org/articles/conquering-sunlight-sensitivity-dersimelagons-promise-photodermatoses/
26. New drug offers hope for rare genetic skin conditions | medtigo, accessed July 3, 2025, https://medtigo.com/news/new-drug-offers-hope-for-rare-genetic-skin-conditions/
27. Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist - PubMed, accessed July 3, 2025, https://pubmed.ncbi.nlm.nih.gov/37060458/
28. Absorption, metabolism, and excretion of [14 C]dersimelagon, an investigational oral selective melanocortin 1 receptor agonist, in preclinical species and healthy volunteers - PubMed, accessed July 3, 2025, https://pubmed.ncbi.nlm.nih.gov/37078227/
29. dersimelagon (MT-7117) / Mitsubishi Tanabe - LARVOL DELTA, accessed July 3, 2025, https://delta.larvol.com/Products/?ProductId=90c00024-f3d1-4cc7-9941-2b11fa4d0a34
30. Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis - PubMed Central, accessed July 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9434962/
31. Erythropoietic Protoporphyria: Phase 2 Clinical Trial Results Evaluating the Safety and Effectiveness of Dersimelagon (MT-7117), an Oral MC1R Agonist | Blood | American Society of Hematology, accessed July 3, 2025, https://ashpublications.org/blood/article/136/Supplement%201/51/472215/Erythropoietic-Protoporphyria-Phase-2-Clinical
32. Dersimelagon in Erythropoietic Protoporphyrias - PubMed, accessed July 3, 2025, https://pubmed.ncbi.nlm.nih.gov/37043653/
33. UCSF Erythropoietic Protoporphyria Clinical Trials — San Francisco Bay Area, accessed July 3, 2025, https://clinicaltrials.ucsf.edu/erythropoietic-protoporphyria
34. A phase 2 study with MT-7117 (dersimelagon) in patients with dcSSc, accessed July 3, 2025, https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-phase-2-study-with-mt-7117-dersimelagon-in-patients-with-dcssc/
35. AB1196 BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN SUBJECTS WITH ILD IN A PHASE 2 STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF MT-7117 IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS, accessed July 3, 2025, https://ard.bmj.com/content/83/Suppl_1/1934
36. Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis - ClinicalTrials.gov, accessed July 3, 2025, https://clinicaltrials.gov/study/NCT04440592?tab=history&a=14
37. Health Technology Briefing June 2022 - NIHR Innovation Observatory, accessed July 3, 2025, https://www.io.nihr.ac.uk/wp-content/uploads/2022/06/26730-TSID_10392-Dersimelagon-for-Erythropoietic-Protoporphyria-V1.0-JUN2022-NON-CONF.pdf
38. EMEA-002850-PIP03-22 - paediatric investigation plan - European Medicines Agency, accessed July 3, 2025, https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002850-pip03-22
39. SCENESSE® for Erythropoietic Protoporphyria - American Porphyria Foundation, accessed July 3, 2025, https://porphyriafoundation.org/for-patients/about-porphyria/treatment-options/scenesse-for-erythropoietic-protoporphyria/
40. Into the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States - JDDonline, accessed July 3, 2025, https://jddonline.com/articles/into-the-light-afamelanotide-and-the-treatment-of-erythropoietic-protoporphyria-in-the-united-states-S1545961623P0941X/
41. How I treat erythropoietic protoporphyria and X-linked protoporphyria | Blood | American Society of Hematology, accessed July 3, 2025, https://ashpublications.org/blood/article/141/24/2921/494865/How-I-treat-erythropoietic-protoporphyria-and-X
42. Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval - SEC.gov, accessed July 3, 2025, https://www.sec.gov/Archives/edgar/data/1816736/000095017024120292/iron-ex99_1.htm
43. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria | Request PDF - ResearchGate, accessed July 3, 2025, https://www.researchgate.net/publication/269468356_Long-term_observational_study_of_afamelanotide_in_115_patients_with_erythropoietic_protoporphyria
44. (PDF) Afamelanotide for Treatment of the Protoporphyrias: Impact on Quality of Life and Laboratory Parameters in a US Cohort - ResearchGate, accessed July 3, 2025, https://www.researchgate.net/publication/380943433_Afamelanotide_for_Treatment_of_the_Protoporphyrias_Impact_on_Quality_of_Life_and_Laboratory_Parameters_in_a_US_Cohort
45. Multicentre Phase III Erythropoietic Protoporphyria Study - ClinicalTrials.gov, accessed July 3, 2025, https://www.clinicaltrials.gov/study/NCT04053270
46. Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission, accessed July 3, 2025, https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-successful-type-c-meeting-fda-bitopertin/
47. I Have Hope for the Future of Erythropoietic Protoporphyria Treatment - Porphyria News, accessed July 3, 2025, https://porphyrianews.com/columns/hope-future-erythropoietic-protoporphyria-treatment/
48. Current trials in erythropoietic protoporphyria: are placebo controls ethical? - PMC, accessed July 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10580501/
49. Scleroderma Pipeline Insight - DelveInsight, accessed July 3, 2025, https://www.delveinsight.com/report-store/scleroderma-pipeline-insight
50. Systemic Sclerosis Pipeline Shows Promise with 50+ Therapies in Development, accessed July 3, 2025, https://trial.medpath.com/news/05cc7f61e1c9000e/systemic-sclerosis-clinical-trials-2024-ema-pdma-fda
51. Systemic Sclerosis (Scleroderma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - GlobalData, accessed July 3, 2025, https://www.globaldata.com/store/report/systemic-sclerosis-scleroderma-drugs-in-development-analysis/
52. Systemic Scleroderma Drug Pipeline Analysis Report 2025 - Expert Market Research, accessed July 3, 2025, https://www.expertmarketresearch.com/clinical-trials/systemic-scleroderma-drug-pipeline-insight
53. Updated EULAR Recommendations on the Treatment of Systemic Sclerosis - RheumNow, accessed July 3, 2025, https://rheumnow.com/news/updated-eular-recommendations-treatment-systemic-sclerosis
54. New promising drugs for the treatment of systemic sclerosis: Pathogenic considerations, enhanced classifications, and personalized medicine - PubMed Central, accessed July 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8292968/
55. Afamelanotide in protoporphyria and other skin diseases: a review - PMC, accessed July 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11110213/
56. Converging Paths Towards Unified Therapeutic Approaches in Atopic Dermatitis, Vitiligo, and Alopecia Areata - PubMed, accessed July 3, 2025, https://pubmed.ncbi.nlm.nih.gov/40274075/
57. Clinical Course of Atopic Dermatitis after Dupilumab Discontinuation: A Multicenter Real-World Study - PubMed, accessed July 3, 2025, https://pubmed.ncbi.nlm.nih.gov/40578600/
58. Challenges and Future Trends in Atopic Dermatitis - MDPI, accessed July 3, 2025, https://www.mdpi.com/1422-0067/24/14/11380
59. Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis - PubMed, accessed July 3, 2025, https://pubmed.ncbi.nlm.nih.gov/34134707/